Base de dados : MEDLINE
Pesquisa : D02.455.426.559.847.562.050.200.650.500 [Categoria DeCS]
Referências encontradas : 104 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 11 ir para página                         

  1 / 104 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22480287
[Au] Autor:Peng R; VanNieuwenhze MS
[Ad] Endereço:Department of Chemistry, 800 East Kirkwood Avenue, Bloomington, Indiana 47405-7102, USA.
[Ti] Título:A model study for constructing the DEF-benzoxocin ring system of menogaril and nogalamycin via a reductive Heck cyclization.
[So] Source:Org Lett;14(8):1962-5, 2012 Apr 20.
[Is] ISSN:1523-7052
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A novel reductive Heck cyclization approach was developed in order to construct a model DEF-benzoxocin ring system that is present in nogalamycin, menogaril, and related anthracycline antitumor antibiotics.
[Mh] Termos MeSH primário: Antibióticos Antineoplásicos/síntese química
Menogaril/síntese química
Nogalamicina/síntese química
[Mh] Termos MeSH secundário: Antibióticos Antineoplásicos/química
Ciclização
Menogaril/química
Modelos Químicos
Estrutura Molecular
Nogalamicina/química
Streptomyces/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 8JSV4O30HQ (Menogaril); L059DCD6IP (Nogalamycin)
[Em] Mês de entrada:1207
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120407
[St] Status:MEDLINE
[do] DOI:10.1021/ol300072h


  2 / 104 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11319290
[Au] Autor:Obasaju C; Manola J; Hudes GR; Khandekar JD; Citrin DL; Carbone P; Trump DL
[Ad] Endereço:Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
[Ti] Título:Phase II evaluation of menogaril in advanced prostate cancer: Eastern Cooperative Oncology Group EST P-A885.
[So] Source:Am J Clin Oncol;24(2):150-4, 2001 Apr.
[Is] ISSN:0277-3732
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Menogaril is a semisynthetic anthracycline that is less cardiotoxic than doxorubicin in a preclinical model. We conducted a phase II trial to determine the activity of menogaril in hormone-refractory prostate cancer. Between October 1985 and November 1987, 32 eligible patients were enrolled and were divided into good- and poor-risk categories, the latter being defined by prior radiotherapy to less than one third of the marrow-containing skeleton. Good-risk patients received a starting dose of 200 mg/m2 by 60-minute IV infusion, whereas the poor-risk patients received 160 mg/m2. Treatment was repeated every 3 weeks until disease progression. Menogaril caused leukopenia in 90% of patients, of whom 47% had grade III or IV toxicity. Thrombocytopenia was uncommon and mild, with only three patients (9%) experiencing grade II toxicity. Nonhematologic toxicity included mucositis (9%), and mild weight loss in 33% of patients. Nine patients (28%) had stable disease of 3 or more months' duration. There were no objective partial or complete responses. The median time to progression for the entire group was 10 weeks, and the median survival time for all patients was 24 weeks. Because of appreciable toxicity and limited antitumor activity, further study of menogaril cannot be recommended in hormone-refractory prostate cancer.
[Mh] Termos MeSH primário: Antibióticos Antineoplásicos/uso terapêutico
Menogaril/uso terapêutico
Neoplasias Hormônio-Dependentes/tratamento farmacológico
Neoplasias da Próstata/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Seres Humanos
Masculino
Meia-Idade
Análise de Sobrevida
[Pt] Tipo de publicação:CLINICAL TRIAL; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 8JSV4O30HQ (Menogaril)
[Em] Mês de entrada:0105
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010425
[St] Status:MEDLINE


  3 / 104 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10955868
[Au] Autor:Kucuk O; Kilton L; Wade JL; Blough R; Benson AB
[Ad] Endereço:Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA. kucuko@karmanos.org
[Ti] Título:Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia.
[So] Source:Am J Clin Oncol;23(4):379-83, 2000 Aug.
[Is] ISSN:0277-3732
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Menogaril is a semisynthetic anthracycline with relative lack of cardiotoxicity. Ten patients with multiple myeloma (MM), seven patients with chronic lymphocytic leukemia (CLL), and one patient with diffuse well-differentiated lymphocytic lymphoma (DWDL) were treated with menogaril, 160 mg/m2 (for MM) or 200 mg/m2 (for CLL/DWDL), given as a 2-hour intravenous infusion, repeated every 28 days. All patients except one with CLL had been previously treated with one chemotherapy regimen and had either not responded or had relapsed after a response to prior treatment. There were no objective responses to treatment. Among the six evaluable patients with MM, two had stable disease with subjective improvement in symptoms for five to 25 cycles, and among the eight patients with CLL/DWDL, five patients remained stable for two to eight cycles on treatment. The remainder of the patients had progressive disease after one to two cycles of chemotherapy. Five grade 4 hematologic toxicities were observed. There was one fatal neutropenic sepsis. Menogaril, as administered in this study, does not appear to have significant activity in patients with previously treated MM or CLL.
[Mh] Termos MeSH primário: Antibióticos Antineoplásicos/uso terapêutico
Leucemia Linfocítica Crônica de Células B/tratamento farmacológico
Menogaril/uso terapêutico
Mieloma Múltiplo/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Anemia/induzido quimicamente
Antibióticos Antineoplásicos/efeitos adversos
Causas de Morte
Progressão da Doença
Feminino
Seguimentos
Seres Humanos
Infusões Intravenosas
Leucopenia/induzido quimicamente
Masculino
Menogaril/efeitos adversos
Meia-Idade
Recidiva Local de Neoplasia/tratamento farmacológico
Neutropenia/induzido quimicamente
Indução de Remissão
Sepse/etiologia
Trombocitopenia/induzido quimicamente
[Pt] Tipo de publicação:CLINICAL TRIAL; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 8JSV4O30HQ (Menogaril)
[Em] Mês de entrada:0009
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:000824
[St] Status:MEDLINE


  4 / 104 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:11550320
[Au] Autor:Hess KR; Wong ET; Jaeckle KA; Kyritsis AP; Levin VA; Prados MD; Yung WK
[Ad] Endereço:Department of Biomathematics, Box 237, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
[Ti] Título:Response and progression in recurrent malignant glioma.
[So] Source:Neuro Oncol;1(4):282-8, 1999 10.
[Is] ISSN:1522-8517
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and 150 with recurrent anaplastic astrocytoma. Median age was 45 years (range, 15-82) and median Karnofsky performance score was 80 (range, 60-100). Forty-one patients (11%) had more than two prior resections and/or more than two prior chemotherapy regimens. Best response was complete (n = 1) or partial (n = 33) in 34 patients (9%). Median time to response was 14 weeks, and median response duration was 44 weeks. Simon-Makuch estimates for 52-week progression-free survival for patients progression-free at 13 weeks were 48% for response and 28% for nonresponse. When response was treated as a time-dependent covariate in a Cox proportional hazards regression analysis, response was associated with significantly lower failure rates (hazard ratio 0.5; 95% confidence interval 0.3-0.8; P = 0.0016). This study showed that response in recurrent glioma is associated with a significant reduction in progression rates.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias Encefálicas/tratamento farmacológico
Glioma/tratamento farmacológico
Recidiva Local de Neoplasia/tratamento farmacológico
[Mh] Termos MeSH secundário: Análise Atuarial
Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Astrocitoma/tratamento farmacológico
Astrocitoma/mortalidade
Astrocitoma/radioterapia
Neoplasias Encefálicas/mortalidade
Neoplasias Encefálicas/radioterapia
Carboplatina/administração & dosagem
Terapia Combinada
Progressão da Doença
Intervalo Livre de Doença
Eflornitina/administração & dosagem
Feminino
Fluoruracila/administração & dosagem
Glioblastoma/tratamento farmacológico
Glioblastoma/mortalidade
Glioblastoma/radioterapia
Glioma/mortalidade
Glioma/radioterapia
Seres Humanos
Interferon beta/administração & dosagem
Masculino
Menogaril/administração & dosagem
Meia-Idade
Recidiva Local de Neoplasia/mortalidade
Procarbazina/administração & dosagem
Prognóstico
Modelos de Riscos Proporcionais
Texas/epidemiologia
Resultado do Tratamento
Tretinoína/administração & dosagem
[Pt] Tipo de publicação:CLINICAL TRIAL; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
1UA8E65KDZ (alitretinoin); 35S93Y190K (Procarbazine); 5688UTC01R (Tretinoin); 77238-31-4 (Interferon-beta); 8JSV4O30HQ (Menogaril); BG3F62OND5 (Carboplatin); U3P01618RT (Fluorouracil); ZQN1G5V6SR (Eflornithine)
[Em] Mês de entrada:0110
[Cu] Atualização por classe:171115
[Lr] Data última revisão:
171115
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010912
[St] Status:MEDLINE
[do] DOI:10.1093/neuonc/1.4.282


  5 / 104 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10638487
[Au] Autor:Moore DF; Brown TD; LeBlanc M; Dahlberg S; Miller TP; McClure S; Fisher RI
[Ad] Endereço:Wichita CCOP, KS, USA.
[Ti] Título:Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial.
[So] Source:Invest New Drugs;17(2):169-72, 1999.
[Is] ISSN:0167-6997
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To assess the efficacy and toxicity of menogaril against non-Hodgkin's lymphoma (NHL) in a group of previously treated patients. PATIENTS AND METHODS: Sixty-two eligible patients with a histologic diagnosis of NHL were enrolled, 35 of who had intermediate or high-grade histologies and 27 of who had low-grade lymphomas. Patients with intermediate or high-grade lymphomas had received only 1 prior chemotherapy regimen, while patients with low-grade histologies had received 1 or 2 prior chemotherapy regimens. Menogaril was administered at 160 mg/m2 intravenously over 1 hour, once every 28 days. RESULTS: Among the 35 patients with intermediate or high-grade lymphomas who were evaluable for response, 6 of 35 patients achieved a partial response (PR) for a response rate of 17% (95% confidence interval: 7%-34%). Median survival in this group of patients was 13 months. For those patients with low-grade lymphoma, 5 of 26 patients achieved a PR for a response rate of 19% (95% confidence interval: 6%-38%). No complete responses were observed in either patient group. The incidence of serious (grade 3 or 4) toxicity for those with intermediate/high-grade and low-grade lymphomas was 43% and 44%, respectively. Most of these toxic effects consisted of reversible myelosuppression. Menogaril was discontinued in 2 patients due to prolonged neutropenia. Cardiotoxicity was observed in 4 patients, requiring discontinuation of the drug in 1 patient. No treatment-related deaths occurred and the overall toxicity was felt to be acceptable. CONCLUSION: The observed antitumor activity of single agent menogaril against both intermediate/high-grade and low-grade lymphomas was modest. Further exploration of this agent in patients with non-Hodgkin's lymphomas does not seem warranted.
[Mh] Termos MeSH primário: Antibióticos Antineoplásicos/efeitos adversos
Antibióticos Antineoplásicos/uso terapêutico
Linfoma não Hodgkin/tratamento farmacológico
Menogaril/efeitos adversos
Menogaril/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Masculino
Meia-Idade
Estadiamento de Neoplasias
Pacientes Desistentes do Tratamento
Taxa de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 8JSV4O30HQ (Menogaril)
[Em] Mês de entrada:0002
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:000119
[St] Status:MEDLINE


  6 / 104 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9438696
[Au] Autor:Ghaemmaghami M; Jett JR
[Ad] Endereço:University of Pittsburgh Cancer Institute and the University of Pittsburgh School of Medicine, USA.
[Ti] Título:New agents in the treatment of small cell lung cancer.
[So] Source:Chest;113(1 Suppl):86S-91S, 1998 Jan.
[Is] ISSN:0012-3692
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The treatment of small cell lung cancer (SCLC) has evolved significantly over the past 3 decades. Single-agent and combination chemotherapies given with radiotherapy have greatly improved response rates and median survival. Combination regimens such as cisplatin/etoposide, carboplatin/etoposide, ifosfamide/carboplatin/etoposide, cyclophosphamide/doxorubicin/vincristine, and etoposide/ifosfamide/cisplatin have all achieved good response rates. Improving long-term survival, however, has remained problematic. Treatment with biological response modifiers (interferons alpha and gamma) has not shown promise in this setting. New agents showing good preliminary single-agent activity in untreated SCLC include paclitaxel, vinorelbine, gemcitabine, topotecan, and teniposide. Results obtained with single-agent docetaxel and CPT-11 are thus far inconclusive. Studies evaluating response and survival rates of these new agents in combination with agents of known activity are underway.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carcinoma de Células Pequenas/tratamento farmacológico
Drogas em Investigação/uso terapêutico
Neoplasias Pulmonares/tratamento farmacológico
Taxoides
[Mh] Termos MeSH secundário: Antibióticos Antineoplásicos/uso terapêutico
Antimetabólitos Antineoplásicos/uso terapêutico
Antineoplásicos Fitogênicos/uso terapêutico
Camptotecina/análogos & derivados
Camptotecina/uso terapêutico
Ensaios Clínicos como Assunto
Desoxicitidina/análogos & derivados
Desoxicitidina/uso terapêutico
Seres Humanos
Fatores Imunológicos/uso terapêutico
Menogaril/uso terapêutico
Paclitaxel/análogos & derivados
Paclitaxel/uso terapêutico
Teniposídeo/uso terapêutico
Topotecan/uso terapêutico
Resultado do Tratamento
Vimblastina/análogos & derivados
Vimblastina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 0 (Antimetabolites, Antineoplastic); 0 (Antineoplastic Agents, Phytogenic); 0 (Drugs, Investigational); 0 (Immunologic Factors); 0 (Taxoids); 0W860991D6 (Deoxycytidine); 15H5577CQD (docetaxel); 5V9KLZ54CY (Vinblastine); 7673326042 (irinotecan); 7M7YKX2N15 (Topotecan); 8JSV4O30HQ (Menogaril); 957E6438QA (Teniposide); B76N6SBZ8R (gemcitabine); P88XT4IS4D (Paclitaxel); Q6C979R91Y (vinorelbine); XT3Z54Z28A (Camptothecin)
[Em] Mês de entrada:9801
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:980123
[St] Status:MEDLINE


  7 / 104 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9341219
[Au] Autor:Sim SP; Gatto B; Yu C; Liu AA; Li TK; Pilch DS; LaVoie EJ; Liu LF
[Ad] Endereço:Department of Pharmacology, UMDNJ-Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA.
[Ti] Título:Differential poisoning of topoisomerases by menogaril and nogalamycin dictated by the minor groove-binding nogalose sugar.
[So] Source:Biochemistry;36(43):13285-91, 1997 Oct 28.
[Is] ISSN:0006-2960
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The effect of DNA binding on poisoning of human DNA TOP1 has been studied using a pair of related anthracyclines which differ only by a nogalose sugar ring. We show that the nogalose sugar ring of nogalamycin, which binds to the minor groove of DNA, plays an important role in affecting topoisomerase-specific poisoning. Using purified mammalian topoisomerases, menogaril is shown to poison topoisomerase II but not topoisomerase I. By contrast, nogalamycin poisons topoisomerase I but not topoisomerase II. Consistent with the biochemical studies, CEM/VM-1 cells which express drug-resistant TOP2alpha are cross-resistant to menogaril but not nogalamycin. The mechanism by which nogalamycin poisons topoisomerase I has been studied by analyzing a major topoisomerase I-mediated DNA cleavage site induced by nogalamycin. This site is mapped to a sequence embedded in an AT-rich region with four scattered GC base pairs (bps) (at -10, -6, +2, and +12 positions). GC bps embedded in AT-rich regions are known to be essential for nogalamycin binding. Surprisingly, DNase I footprinting analysis of nogalamycin-DNA complexes has revealed a drug-free region from -2 to +9 encompassing the major cleavage site. Our results suggest that nogalamycin, in contrast to camptothecin, may stimulate TOP1 cleavage by binding to a site(s) distal to the site of cleavage.
[Mh] Termos MeSH primário: DNA Topoisomerases Tipo I/efeitos dos fármacos
DNA/efeitos dos fármacos
DNA/metabolismo
Menogaril/toxicidade
Metilmanosídeos/metabolismo
Nogalamicina/toxicidade
[Mh] Termos MeSH secundário: Antibacterianos/toxicidade
Sequência de Bases/efeitos dos fármacos
Dano ao DNA/efeitos dos fármacos
Pegada de DNA
DNA Topoisomerases Tipo I/fisiologia
DNA Topoisomerases Tipo II/metabolismo
Desoxirribonuclease I
Estabilidade Enzimática/efeitos dos fármacos
Metilmanosídeos/química
Nogalamicina/química
Tetraciclinas
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Methylmannosides); 0 (Tetracyclines); 30319-19-8 (nogalose); 8JSV4O30HQ (Menogaril); 9007-49-2 (DNA); EC 3.1.21.1 (Deoxyribonuclease I); EC 5.99.1.2 (DNA Topoisomerases, Type I); EC 5.99.1.3 (DNA Topoisomerases, Type II); L059DCD6IP (Nogalamycin)
[Em] Mês de entrada:9711
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:971028
[St] Status:MEDLINE


  8 / 104 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9279344
[Au] Autor:Taguchi T; Wakui A; Niitani H; Furue H; Majima H; Ota K; Ariyoshi H; Hattori T; Sugimachi K; Tsukagoshi S
[Ad] Endereço:Research Institute for Microbial Diseases, Osaka University.
[Ti] Título:[TUT-7 early phase II clinical study for various solid tumors and hematologic malignancies].
[So] Source:Gan To Kagaku Ryoho;24(10):1253-61, 1997 Aug.
[Is] ISSN:0385-0684
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:An early Phase II study with TUT-7 (menogaril), a new anthracycline antitumor antibiotic, was conducted in patients with various malignant tumors at 81 departments of 65 institutions nationwide. One course of TUT-7 treatment consisted of seven (7) or fourteen (14) consecutive days of administration at 75 or 100 mg/body/day with two-week drug withdrawal; at least two courses of treatment were given in principle. Among the 165 patients registered, 145 patients were eligible and 128 patients were evaluable for antitumor efficacy. In 11 patients with malignant lymphoma, one (1) had CR and five (5) had PR (54.5%); in three (3) patients with prostate cancer, one (1) had PR (33.3%); and in 12 patients with uterine cervical cancer, two (2) had PR (16.7%). Adverse drug reactions frequently observed were digestive organ disorders (anorexia and nausea/vomiting) and malaise. The abnormality in laboratory tests observed frequently was myelosuppression (leukopenia and neutropenia).
[Mh] Termos MeSH primário: Antibióticos Antineoplásicos/uso terapêutico
Neoplasias Gastrointestinais/tratamento farmacológico
Neoplasias Hematológicas/tratamento farmacológico
Menogaril/uso terapêutico
Neoplasias Urológicas/tratamento farmacológico
Neoplasias do Colo do Útero/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Anorexia/induzido quimicamente
Antibióticos Antineoplásicos/efeitos adversos
Esquema de Medicação
Feminino
Seres Humanos
Leucopenia/induzido quimicamente
Masculino
Menogaril/efeitos adversos
Meia-Idade
Náusea/induzido quimicamente
Neutropenia/induzido quimicamente
Sistema de Registros
Vômito/induzido quimicamente
[Pt] Tipo de publicação:CLINICAL TRIAL; CLINICAL TRIAL, PHASE II; CONTROLLED CLINICAL TRIAL; ENGLISH ABSTRACT; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 8JSV4O30HQ (Menogaril)
[Em] Mês de entrada:9709
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:970801
[St] Status:MEDLINE


  9 / 104 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9279345
[Au] Autor:Taguchi T; Ohta K; Hotta T; Shirakawa S; Masaoka T; Kimura I
[Ad] Endereço:Osaka University.
[Ti] Título:[Menogaril (TUT-7) late phase II study for malignant lymphoma, adult T-cell leukemia and lymphoma (ATLL)].
[So] Source:Gan To Kagaku Ryoho;24(10):1263-71, 1997 Aug.
[Is] ISSN:0385-0684
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:A late Phase II multicenter study with menogaril was conducted nationwide in patients with malignant lymphoma [non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD)], and ATLL, menogaril was orally administered at 100 mg daily after breakfast, for seven consecutive days with two- or three-week drug withdrawal, then menogaril administration was repeated. For malignant lymphoma, in 81 patients with NHL and 5 patients with HD registered, 70 and 5 patients were evaluable for efficacy, respectively. The efficacy rates were 32.9% (6 CRs + 17 PRs/70) for NHL and 20.0% (1 PR/5) for HD, respectively; that for the NHL patients with prior anthracycline antibiotic chemotherapy was 30.5% (5 CRs and 13 PRs/59). For ATLL, among the 16 patients registered, 15 were evaluable for efficacy, and the efficacy rate was 40.0% (2 CRs and 4 PRs/15). Adverse drug reactions frequently observed in the patients with malignant lymphoma and ATLL included bone-marrow suppression and gastrointestinal symptoms such as anorexia, and nausea/vomiting. With these results, menogaril was considered to be effective for the treatment of non-Hodgkin's lymphoma and ATLL.
[Mh] Termos MeSH primário: Antibióticos Antineoplásicos/administração & dosagem
Doença de Hodgkin/tratamento farmacológico
Leucemia-Linfoma de Células T do Adulto/tratamento farmacológico
Linfoma não Hodgkin/tratamento farmacológico
Menogaril/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Idoso
Anorexia/induzido quimicamente
Antibióticos Antineoplásicos/efeitos adversos
Medula Óssea/efeitos dos fármacos
Esquema de Medicação
Feminino
Seres Humanos
Masculino
Menogaril/efeitos adversos
Meia-Idade
Náusea/induzido quimicamente
Vômito/induzido quimicamente
[Pt] Tipo de publicação:CLINICAL TRIAL; CLINICAL TRIAL, PHASE II; ENGLISH ABSTRACT; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 8JSV4O30HQ (Menogaril)
[Em] Mês de entrada:9709
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM; X
[Da] Data de entrada para processamento:970801
[St] Status:MEDLINE


  10 / 104 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:9239166
[Au] Autor:Taguchi T; Wakui A; Niitani H; Furue H; Majima H; Nakao I; Ota K; Hattori T; Sugimachi K
[Ad] Endereço:Research Institute for Microbial Diseases, Osaka University (Japan Society for Cancer Chemotherapy at present).
[Ti] Título:[TUT-7 phase I clinical study. TUT-7 Study Group].
[So] Source:Gan To Kagaku Ryoho;24(9):1125-33, 1997 Jul.
[Is] ISSN:0385-0684
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:A phase I study with TUT-7, a new anthracycline antitumor antibiotic, was conducted in 35 malignant tumor patients at 11 institutions nationwide. The study was initiated with a single dose at 100 mg/body which was equivalent to 2n, then the dose as escalated up to 700 mg/body in accordance with the modified Fibonacci's scheme. The dose limiting factor (DLF) was considered to be leukopenia, and maximum tolerated dose (MTD) was 700 mg/ body. The consecutive days dosing study subsequently conducted started with 25 mg/body/day, and the dose level was escalated up to 150 mg /body/day. TUT-7 was orally administered for seven (7) to fourteen (14) consecutive days in principle. It was considered that DLF was leukopenia and MTD was 100 mg/body/day for consecutive days dosing. The study indicated that serum drug concentrations reached their plateaus on the 5th day after initiation of TUT-7 treatment and the accumulation of this compound was low. With these findings, a regimen with a dose of 100 mg/body/day orally administered for 14 consecutive days was recommended for early phase II studies.
[Mh] Termos MeSH primário: Antibióticos Antineoplásicos/administração & dosagem
Menogaril/administração & dosagem
Neoplasias/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Oral
Idoso
Antibióticos Antineoplásicos/sangue
Antibióticos Antineoplásicos/farmacocinética
Neoplasias da Mama/tratamento farmacológico
Neoplasias da Mama/metabolismo
Neoplasias do Colo/tratamento farmacológico
Neoplasias do Colo/metabolismo
Esquema de Medicação
Feminino
Seres Humanos
Neoplasias Pulmonares/tratamento farmacológico
Neoplasias Pulmonares/metabolismo
Masculino
Menogaril/sangue
Menogaril/farmacocinética
Meia-Idade
Neoplasias/metabolismo
Neoplasias Pancreáticas/tratamento farmacológico
Neoplasias Pancreáticas/metabolismo
[Pt] Tipo de publicação:CLINICAL TRIAL; CLINICAL TRIAL, PHASE I; ENGLISH ABSTRACT; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 8JSV4O30HQ (Menogaril)
[Em] Mês de entrada:9708
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:970701
[St] Status:MEDLINE



página 1 de 11 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde